Endoron's Endostapling Device for AAA Repair Gains Funding From Sofinnova Partners

December 14, 2021—Sofinnova Partners, a European life sciences venture capital firm, announced the placement of $5 million in seed funding for Endoron Medical to accelerate the development of the company’s endograft stapling solution for endovascular repair of abdominal aortic aneurysms (AAA). This is the third investment from its medtech acceleration fund, Sofinnova MD Start III.

Sofinnova Partners advised that the proceeds from the financing round will provide working capital to accelerate the full validation of the catheter-based Endoron endostapling device. Additionally, the funds will support the regulatory strategy in preparation for the initial clinical experience, which will aim to establish safety, feasibility, and efficacy of the company’s endovascular suturing technology.

According to Sofinnova Partners, the Endoron endostapling device for AAA repair is designed to secure an endograft's fixation and to improve sealing mechanisms. In addition, the stapling mechanisms developed by Endoron can be used to repair endovascular grafts that have migrated away from the implant site and have developed endoleaks that require augmented fixation and sealing to regain or maintain effective aneurysm exclusion.

Endoron Medical, which was founded in 2019, builds on an invention from Professor Ron Karmeli, MD, from Hadassah Hospital in Jerusalem, Israeli. Prof. Karmeli is cofounder and Chief Medical Officer of Endoron.

Cécile Dupont, Senior Associate and Program Director at Sofinnova Partners, will join the Endoron management team to bring operational and strategic support to accelerate the development of the company's technology.